23rd Sep 2013 10:31
LONDON (Alliance News) - Vectura Group PLC said that its once-daily dual bronchodilator, known as Ultibro Breezhaler, has gained European approval to treat adult patients in Europe with chronic obstructive pulmonary disease.
The company engaged in developing treatments for respiratory diseases, said that Ultibro Breezhaler has been been approved by the European Commission, as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease.
It said that the new inhaled, once-daily, fixed-dose bronchodilator combines the benefits of two established Novartis COPD treatments, which are already widely available in countries across the world, the Onbrez Breezhaler and the Seebri Breezhaler.
"This innovative, once-daily therapy provides another option for patients to address unmet needs associated with their disease and improve their quality of life. The approval of QVA149 in the EU triggers a $10 million milestone to Vectura," said Chief Executive Chris Blackwell in a statement.
Vectura shares were trading at 110.83 pence apiece Monday, down 1.5%.
By Rowena Harris-Doughty; [email protected]; @rharrisdoughty
Copyright 2013 Alliance News Limited. All Rights Reserved.
Related Shares:
VEC.L